Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries
- PMID: 14625623
Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries
Abstract
Cardiovascular diseases are the primary cause of mortality in France. Many epidemiological studies have shown that the total homocysteine concentration is a risk indicator for cardiovascular disease. Furthermore, it has been shown that the homocysteine concentration can be effectively lowered by supplementation with folic acid, vitamin B6 and B12. However, it is not yet known whether a reduction of the homocysteine concentration by such a supplementation indeed leads to a decreased risk of cardiovascular disease. Another possible dietary factor that may lower the risk of cardiovascular disease is fish-oil, which is rich in omega-3 fatty acids. These fatty acids lower platelet aggregation and triglyceride rich lipoproteins and may have antiarrhythmic effects. Some trials have investigated the effect of fish or fish-oil on cardiovascular mortality, and the results, although not conclusive, suggest a protective effect of a higher intake. In the SU.FOL.OM3 study we will evaluate the effect of supplementation at nutritional doses of folate (in the natural 5-methyl-tetrahydrofolate form) in combination with vitamin B6 and B12 and/or omega-3 fatty acids and/or placebo on recurrent ischemic diseases in a factorial design. The supplements will be randomly allocated to the participants in a double-blind fashion. In total 3,000 patients aged between 45 and 80 years who had a past history of myocardial infarction or unstable angina pectoris or an ischemic stroke will be included. The participants will be supplemented and followed up for a period of five years.
Similar articles
-
B vitamin and/or ω-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial.Arch Intern Med. 2012 Apr 9;172(7):540-7. doi: 10.1001/archinternmed.2011.1450. Epub 2012 Feb 13. Arch Intern Med. 2012. PMID: 22331983 Clinical Trial.
-
Evidence for a protective (synergistic?) effect of B-vitamins and omega-3 fatty acids on cardiovascular diseases.Eur J Clin Nutr. 2004 May;58(5):732-44. doi: 10.1038/sj.ejcn.1601871. Eur J Clin Nutr. 2004. PMID: 15116076
-
Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.Semin Thromb Hemost. 2000;26(3):341-8. doi: 10.1055/s-2000-8101. Semin Thromb Hemost. 2000. PMID: 11011852 Review.
-
Effect of multivitamin supplementation on the homocysteine and methylmalonic acid blood concentrations in women over the age of 60 years.Eur J Nutr. 2005 Mar;44(3):183-92. doi: 10.1007/s00394-004-0510-2. Epub 2004 May 19. Eur J Nutr. 2005. PMID: 15309436 Clinical Trial.
-
Vitamins and stroke: the homocysteine hypothesis still in doubt.Neurologist. 2008 Jan;14(1):2-4. doi: 10.1097/01.nrl.0000253066.85963.aa. Neurologist. 2008. PMID: 18195649 Review.
Cited by
-
Marine-derived n-3 fatty acids therapy for stroke.Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD012815. doi: 10.1002/14651858.CD012815.pub3. Cochrane Database Syst Rev. 2022. PMID: 35766825 Free PMC article. Review.
-
Effects of vitamin supplements on clinical cardiovascular outcomes: Time to move on! - A comprehensive review.Clin Nutr ESPEN. 2021 Apr;42:1-14. doi: 10.1016/j.clnesp.2021.02.014. Epub 2021 Feb 25. Clin Nutr ESPEN. 2021. PMID: 33745562 Free PMC article. Review.
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2020 Feb 29;3(3):CD003177. doi: 10.1002/14651858.CD003177.pub5. Cochrane Database Syst Rev. 2020. PMID: 32114706 Free PMC article.
-
Marine-derived n-3 fatty acids therapy for stroke.Cochrane Database Syst Rev. 2019 Jun 26;6(6):CD012815. doi: 10.1002/14651858.CD012815.pub2. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2022 Jun 29;6:CD012815. doi: 10.1002/14651858.CD012815.pub3. PMID: 31242320 Free PMC article. Updated.
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Nov 30;11(11):CD003177. doi: 10.1002/14651858.CD003177.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 Feb 29;3:CD003177. doi: 10.1002/14651858.CD003177.pub5. PMID: 30521670 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous